|
|
|
|
|
|
|
|
|
|
CONCLUSIONS: Antibodies to p53 are detected in the sera of 42% of patients with advanced serous ovarian cancer.
Impact: Although their utility as a preoperative diagnostic biomarker, beyond CA 125 and HE4, is limited, p53-AAb are prognostic for improved overall survival.
Cancer Epidemiol Biomarkers Prev
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.